TREML1 and glioblastoma: Furthermore, despite the significant reduction of plasma Tlt1, its concentration remained higher at day 93 than in HBDs (HBDs: 0.77 ng/ml vs. anti-GBM: 3.05 ng/ml, ∗P < 0.05), suggesting that chronic platelet activation was not abrogated by the treatment.